Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.

doi:10.1016/j.bioorg.2022.106057

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.

Bioorganic chemistry - 1 Nov 2022

Zhao Hong-Yi, Xi Xiao-Xiao, Xin Minhang, Zhang San-Qi

Abstract excerpt

The third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have accomplished impressive clinical achievements in the treatment of non-small-cell lung cancer (NSCLC). Nonetheless, the acquired drug resistance largely limits their clinical use. The tertiary C797S mutation in the kinase domain of EGFR is one of the major mechanisms responsible for the drug resistance. Therefore,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm
Share to ErbB Receptors
Share to Lung Neoplasms
Share to Mutation
Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 35964503
DOI: 10.1016/j.bioorg.2022.106057

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics